Bcl-2 family in non-small cell lung cancer: its prognostic and therapeutic implications
Ping-Li Sun1, Hironobu Sasano2, Hongwen Gao1
1Department of Pathology, The Second Hospital of Jilin University, Jilin, China, 218 Ziqiang Road, Changchun, Jilin 130041, China.
Abstract:
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Despite significant advances in its research of tumor biology and therapy, the prognosis for this neoplasm has still remained poor. The great majority of anticancer agents, regardless of their mechanisms of action, exert their lethal actions on cancer cells by inducing apoptosis following drug-induced cellular damage. Many reported studies have evaluated the prognostic and therapeutic implications of apoptosis in lung cancer, but their exact clinical value has remained unclear. Therefore more prospective studies are currently required to further validate apoptosis as prognostic and predictive biomarkers in lung cancer patients. The current study reviewed the studies on the prognostic and predictive significances of Bcl-2 family proteins in NSCLC. We also discussed potential treatment strategies which could target apoptotic proteins in lung carcinoma cells. Exception for Bcl-2 itself, studies of the prognostic significance of other Bcl-2 family proteins is markedly limited. The abundance of literature suggests that targeting apoptosis in NSCLC is feasible. However, many troubling questions arise with the use of new drugs or treatment strategies, and new biomarkers are needed.
Insights
Apoptosis research in non-small cell lung cancer (NSCLC) shows promise for targeted therapies. However, more studies are needed to confirm apoptosis and Bcl-2 family proteins as reliable biomarkers for NSCLC patient prognosis and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
- Apoptosis, or programmed cell death, is a key mechanism targeted by many anti-cancer drugs.
- The prognostic and therapeutic roles of apoptosis in NSCLC require further elucidation.
Purpose of the Study:
- To review the prognostic and predictive significance of Bcl-2 family proteins in NSCLC.
- To discuss potential therapeutic strategies targeting apoptotic proteins in NSCLC.
- To identify the need for further research and novel biomarkers.
Main Methods:
- Literature review of studies on Bcl-2 family proteins in NSCLC.
- Analysis of the prognostic and predictive implications of apoptosis.
- Discussion of targeted treatment strategies.
Main Results:
- Limited studies exist on the prognostic significance of Bcl-2 family proteins, excluding Bcl-2 itself.
- Targeting apoptosis in NSCLC appears feasible based on existing literature.
- The clinical value of apoptosis as a biomarker in NSCLC is not yet clearly established.
Conclusions:
- Further prospective studies are essential to validate apoptosis and Bcl-2 family proteins as prognostic and predictive biomarkers in NSCLC.
- Targeting apoptotic pathways presents a viable therapeutic avenue for NSCLC.
- Development of new biomarkers is crucial for advancing NSCLC treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation